Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

15.01 -0.09 (-0.63%)
Streaming Delayed Price Updated: 1:29 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 376,880
Open 15.20
Bid (Size) 15.00 (7)
Ask (Size) 15.01 (2)
Prev. Close 15.10
Today's Range 14.94 - 15.23
52wk Range 11.09 - 17.77
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-12.30%
-12.30%
1 Month
-5.39%
-5.39%
3 Month
-0.96%
-0.96%
6 Month
+19.75%
+19.75%
1 Year
-9.17%
-9.17%

More News

Read More
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
Via Benzinga
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
Via Benzinga
Earnings Preview For Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Via InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
Via InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
Via Investor's Business Daily
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
Via The Motley Fool
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks You May Want To Dump In Q1
Via Benzinga
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months
Via Benzinga
Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances
Via InvestorPlace
Topics Economy
Exposures Economy
3 Biotech Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024
Via The Motley Fool
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January
Via InvestorPlace
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.